Clinical Trials Logo

Clinical Trial Summary

Patients with diagnostic CMR images for assessment of LGE/fibrosis and evidence/presence of non-ischaemic myocardial fibrosis/scar will be randomized to the following treatment groups in a 1:1 ratio: ICD group or Optimal HF care group.


Clinical Trial Description

The primary objective of this study is to evaluate the hypothesis that implantable cardioverter defibrillator (ICD) therapy would decrease the risk of death from any cause in comparison to optimal heart failure (HF) care without ICD insertion in patients with NIDCM, left ventricular ejection fraction (LVEF) ≤35% and presence of myocardial fibrosis on cardiac magnetic resonance (CMR) imaging. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04558723
Study type Interventional
Source University of Luebeck
Contact Ingo Eitel, Prof. Dr.
Phone +49 451 500 44501
Email ingo.eitel@uksh.de
Status Recruiting
Phase N/A
Start date January 14, 2021
Completion date November 2027

See also
  Status Clinical Trial Phase
Recruiting NCT06055504 - Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1) N/A
Terminated NCT03249272 - Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Phase 4
Recruiting NCT05769036 - Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients N/A
Recruiting NCT03797092 - Stem Cell Therapy in Non-IschEmic Non-treatable Dilated CardiomyopathiEs II: a Pilot Study Phase 1/Phase 2
Recruiting NCT04476901 - Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy Phase 2
Completed NCT01392625 - PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study) Phase 1/Phase 2
Not yet recruiting NCT05760924 - Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders N/A
Completed NCT04325594 - The Application of the Umbilical Cord Mesenchymal Stem Cells in the Complex Treatment of Non-ischemic Heart Failure Phase 2